Safety reporting under MDR in The Netherlands part III

In this video, the following question is briefly answered:

When does vigilance reporting apply and who is responsible for this process?”

 

Transcript:

 

In this “trilogy” we talk about the safety reporting of different legal frameworks in The Netherlands.

 

The last 2 weeks we talked about safety reporting for clinical investigations that are conducted for conformity purposes and other clinical investigations.

 

Today, we are going to briefly answer the question:

 

When does vigilance reporting apply and who is responsible for this process?

 

When it comes to clinical investigations with medical devices that bear the CE marking and the investigation is conducted within the scope of the intended use with invasive or burdensome procedures added to the conduct of the investigation, this so-called post-market clinical follow-up falls under art. 74.1.

 

In addition to the safety reporting of procedure related events of these PMCFs, as mentioned in part 1 of this trilogy, vigilance reporting applies when any serious incidents related to the device occurred, including field safety corrective actions.

 

This vigilance reporting is the responsibility of the manufacturer.

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Other articles

Clinical Investigations

Safety reporting under MDR in The Netherlands part III

In this video, the following question is briefly answered: “When does vigilance reporting apply and who is responsible for this process?”   Transcript:   In this “trilogy” we talk about the safety reporting of different legal frameworks in The Netherlands.   The last 2 weeks we talked about safety reporting for clinical investigations that are

Clinical Investigations

Safety reporting under MDR in The Netherlands part II

In this video, the following question is briefly answered: “How do clinical investigations under article 82 comply with safety reporting in The Netherlands?”   Transcript:   Last week, we began looking at safety reporting. Today, we’re going to briefly focus on the following follow-up question:   How do clinical investigations under article 82 comply with

Scroll naar top